4.5 Article

Assessment of Passive Intestinal Permeability Using an Artificial Membrane Insert System

Journal

JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 107, Issue 1, Pages 250-256

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.xphs.2017.08.002

Keywords

artificial membrane insert system (AMI-system); regenerated cellulose; Caco-2 cells; intestinal absorption; apparent permeability coefficient; FaSSIF/FaHIF

Funding

  1. Innovative Medicines Initiative Joint Undertaking [115369]
  2. European Union's Seventh Framework Program
  3. EFPIA companies
  4. Research Foundation-Flanders (FWO) [G.0769.14N]

Ask authors/readers for more resources

Despite reasonable predictive power of current cell-based and cell-free absorption models for the assessment of intestinal drug permeability, high costs and lengthy preparation steps hamper their use. The use of a simple artificial membrane (without any lipids present) as intestinal barrier substitute would overcome these hurdles. In the present study, a set of 14 poorly water-soluble drugs, dissolved in 2 different media (fasted state simulated/human intestinal fluids [FaSSIF/FaHIF]), were applied to the donor compartment of an artificial membrane insert system (AMI-system) containing a regenerated cellulose membrane. Furthermore, to investigate the predictive capacity of the AMI-system as substitute for the well-established Caco-2 system to assess intestinal permeability, the same set of 14 drugs dissolved in FaHIF were applied to the donor compartment of a Caco-2 system. For 14 drugs, covering a broad range of physicochemical parameters, a reasonable correlation between both absorption systems was observed, characterized by a Pearson correlation coefficient r of 0.95 (FaHIF). Using the AMI-system, an excellent predictive capacity of FaSSIF as surrogate medium for FaHIF was demonstrated (r = 0.96). Based on the acquired data, the AMI-system appears to be a time-and cost-effective tool for the early-stage estimation of passive intestinal permeability for poorly water-soluble drugs. (c) 2018 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available